Education
About Us
Working with TipRanks
Follow Us
Mind Medicine Inc. (MNMD)
:MNMD
MNMD Stock Chart & Stats
Day’s Range― - ―
52-Week Range$5.03 - $12.22
Previous CloseN/A
Volume779.86K
Average Volume (3M)2.07M
Market Cap
$495.92M
Enterprise Value$185.59M
Total Cash (Recent Filing)$273.74M
Total Debt (Recent Filing)$21.85M
Price to Earnings (P/E)―
Beta2.06
Next Earnings
May 14, 2025EPS Estimate
-0.36Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.91
Shares Outstanding75,368,360
10 Day Avg. Volume1,023,743
30 Day Avg. Volume2,065,435
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-4.90
P/FCF Ratio0.00
Enterprise Value/Market Cap0.37
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-1.75
Forecast
1Y Price Target
$23.22Price Target Upside268.57% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
---
Bulls Say, Bears Say
Bulls Say
Cash PositionMindMed ended 2024 with $274M in cash which it expects will be sufficient to fund operations into 2027.
Phase 3 TrialsSolid enrollment and maintained Phase 3 data timelines are encouraging.
Regulatory ProgressMindMed announced it has secured alignment with the FDA, including a reduction in required treatment session duration to 8 hours, which strengthens the feasibility of MM120 as a commercial therapy.
Bears Say
Execution RiskMindMed's lead compound, MM120, appears positioned to disrupt the treatment paradigm for generalized anxiety disorder (GAD) and major depressive disorder (MDD), indications with high unmet need in neuropsychiatry.
Market CompetitionThe emerging psychedelics space has clear FDA guidance for regulatory approval, which is a positive signal for Mind Medicine Inc.
---
Ownership Overview
3.29% Insiders
5.33% Mutual Funds
23.83% Other Institutional Investors
59.35% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
MNMD FAQ
What was Mind Medicine Inc.’s price range in the past 12 months?
Mind Medicine Inc. lowest stock price was $5.03 and its highest was $12.22 in the past 12 months.
What is Mind Medicine Inc.’s market cap?
Mind Medicine Inc.’s market cap is $495.92M.
When is Mind Medicine Inc.’s upcoming earnings report date?
Mind Medicine Inc.’s upcoming earnings report date is May 14, 2025 which is in 47 days.
How were Mind Medicine Inc.’s earnings last quarter?
Mind Medicine Inc. released its earnings results on Mar 06, 2025. The company reported -$0.41 earnings per share for the quarter, missing the consensus estimate of -$0.293 by -$0.117.
Is Mind Medicine Inc. overvalued?
According to Wall Street analysts Mind Medicine Inc.’s price is currently Undervalued.
Does Mind Medicine Inc. pay dividends?
Mind Medicine Inc. does not currently pay dividends.
What is Mind Medicine Inc.’s EPS estimate?
Mind Medicine Inc.’s EPS estimate is -0.36.
How many shares outstanding does Mind Medicine Inc. have?
Mind Medicine Inc. has 75,368,360 shares outstanding.
What happened to Mind Medicine Inc.’s price movement after its last earnings report?
Mind Medicine Inc. reported an EPS of -$0.41 in its last earnings report, missing expectations of -$0.293. Following the earnings report the stock price went up 3.605%.
Which hedge fund is a major shareholder of Mind Medicine Inc.?
Currently, no hedge funds are holding shares in MNMD
---
Mind Medicine Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$23.22 (268.57% Upside)
$23.22 (268.57% Upside)
Blogger Sentiment
Bullish
MNMD Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 806.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $17.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.1%
Last 30 Days ▼ 3.6%
Last 30 Days ▼ 3.6%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-33.26%
12-Months-Change
Fundamentals
Return on Equity
-68.01%
Trailing 12-Months
Asset Growth
142.61%
Trailing 12-Months
Company Description
Mind Medicine Inc.
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder, as well as for the treatment of chronic pain; and MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. It also develops MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company is headquartered in Vancouver, Canada.
---
MNMD Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted MindMed's strong financial position and progress towards Phase III trials, while also acknowledging rising R&D expenses and a net loss. The sentiment leans towards positive due to the company's strong cash reserves and clear roadmap for advancing clinical trials.Read More>---
MNMD Stock 12 Month Forecast
Average Price Target
$23.22
▲(268.57% Upside)
Technical Analysis
Best Analysts Covering MNMD
1 Year
1 Year Success Rate
11/22 ratings generated profit
1 Year Average Return
+33.50%
reiterated a buy rating 22 days ago
Copying Patrick Trucchio's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +33.50% per trade.
---